What is the EMMA – Endometrial Microbiome Metagenomic Analysis test?
EMMA is a test that analyses the endometrial microbiome to help identify abnormalities associated with a poor reproductive prognosis.
EMMA indicates the endometrial microbiome balance, providing information on the proportions of all endometrial bacteria, including those linked to higher pregnancy rates. EMMA also includes ALICE, which detects pathogenic bacteria that can cause chronic endometritis.
What is the procedure?
EMMA can be performed on a small piece of an endometrial biopsy.
Why use EMMA test?
EMMA uses the latest Next Generation Sequencing (NGS) technology to provide endometrial microbiome information by analysing the complete profile of the bacteria present in the tissue
EMMA can determine the percentage of Lactobacillus present in the endometrium; low proportions of Lactobacillus are associated with poor reproductive outcomes
EMMA includes the ALICE test, so it indicates the possible presence of bacteria that can cause chronic endometritis, further other pathogenic bacteria.
If the endometrium is non-Lactobacillus dominated, the report will suggest the adequate treatment for each patient
EMMA will determine whether the uterine microbial environment is optimal or not for embryo implantation
Who should use the EMMA?
Patients with repeated implantation failure (RIF)
EMMA can be beneficial for any patient wishing to conceive, by assessing the microbiological environment that the embryo will encounter at implantation
*Moreno et al., 2016
These tests are not able to detect resistance to antibiotics
The tests are not 100% accurate at determining the bacterial species.
A negative result doesn’t rule out the presence of other endometrial pathogens
We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.